MedWatch

Pharmaceutical industry sets its sight on huge savings

Danish pharma giants Novo Nordisk and Lundbeck believe that common rules for medicine approvals could save the industry billions.

Foto: JENS DRESLING, Jyllands-Posten

In recent years the US, EU and Japan has conformed requirements for the approval of new medicine significantly and it has saved Danish pharmaceutical companies billions of kroner. But now, Novo Nordisk and Lundbeck urge authorities to go all the way and collaborate on a global scale.

“We need global rules for approval. There has been a harmonizing in Europe and Japan and the US, but at the same time we see China and Brazil introducing new ways of reviewing applications. That way it becomes more and more expensive to develop new drugs,” says Lars Rebien Sørensen, CEO of Novo Nordisk.

Læs hele artiklen

Få 14 dages fri adgang.

Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier